OAKLAND, Calif., May 20, 2021 -- Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on Wednesday, May 26, 2021. Koya Founder, CEO and President Andy Doraiswamy, Ph.D., will provide an overview of Koya's recent business milestones and developments with the company's product, Dayspring™, the first FDA-cleared, wearable and mobility-enabled compression system for the treatment of lymphedema and venous diseases. The Company's presentation will be available throughout the day on May 26 to all conference participants.
The Oppenheimer MedTech, Tools & Diagnostics Summit investor conference will be held virtually. Institutional investors who wish to schedule a meeting with Koya management can contact their Oppenheimer sales representative or Damian Rippole at damian@koyamedical.com.
About Koya Medical
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases to increase movement, mobility and personalized care that is unavailable with traditional compression therapy. The privately held company was founded in 2018 with the mission to transform lymphatic and vein care through innovative patient-centric platforms. For company or product inquiry, contact info@koyamedical.com. Follow the company on LinkedIn at www.linkedin.com/company/koyamedical/.
About Dayspring™
The Dayspring system is the first wearable and mobility-enabled compression system designed with real life in mind. It is the first and only compression therapy option designed to enable movement, mobility and personalized care that is unavailable with traditional compression therapy. The Dayspring system includes a low-profile active garment made of soft, breathable mesh using Koya's proprietary Flexframe™ technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to program custom treatment options.
Dayspring has received FDA 510(k) clearance for the treatment of lymphedema and other similar conditions that impact lymphatic flow in upper extremities.
